Bisphosphonates pathway.
作者信息
Gong Li, Altman Russ B, Klein Teri E
机构信息
Department of Genetics, Stanford University, Stanford, California, USA.
出版信息
Pharmacogenet Genomics. 2011 Jan;21(1):50-3. doi: 10.1097/FPC.0b013e328335729c.
Abstract
摘要
相似文献
1
Bisphosphonates pathway.
Pharmacogenet Genomics. 2011 Jan;21(1):50-3. doi: 10.1097/FPC.0b013e328335729c.
2
Long-term use of bisphosphonates in osteoporosis.
J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19.
3
[Bisphosphonate treatment of osteoporosis and other skeletal diseases].
Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):244-7. doi: 10.4045/tidsskr.09.0470.
4
[Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149.
5
[When should bisphosphonate treatment be discontinued?].
Tidsskr Nor Laegeforen. 2012 Aug 7;132(14):1630-2. doi: 10.4045/tidsskr.11.0788.
6
Ibandronate in profile: drug characteristics and clinical efficacy.
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941.
7
Bisphosphonates: how do they work?
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):831-47. doi: 10.1016/j.beem.2008.07.001.
8
Zoledronic acid: a review of its use in the treatment of osteoporosis.
Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007.
9
Bisphosphonates for osteoporosis--where do we go from here?
N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9.
10
Bisphosphonates for osteoporosis: benefits and risks.
J Clin Endocrinol Metab. 2011 Sep;96(9):27A, 28A. doi: 10.1210/jcem.96.9.zeg27a.
引用本文的文献
1
Mechanisms of Ellagic Acid (EA)-Mediated Osteogenic Differentiation of Human Dental Pulp-Derived Stem Cells.
ACS Omega. 2025 Apr 13;10(15):15229-15242. doi: 10.1021/acsomega.4c10642. eCollection 2025 Apr 22.
2
Asperuloside alleviates osteoporosis by promoting autophagy and regulating Nrf2 activation.
J Orthop Surg Res. 2024 Dec 19;19(1):855. doi: 10.1186/s13018-024-05320-8.
3
Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis.
Int J Mol Sci. 2024 May 22;25(11):5623. doi: 10.3390/ijms25115623.
4
Multifunctional electrospun nanofibrous scaffold enriched with alendronate and hydroxyapatite for balancing osteogenic and osteoclast activity to promote bone regeneration.
Front Bioeng Biotechnol. 2023 Nov 9;11:1302594. doi: 10.3389/fbioe.2023.1302594. eCollection 2023.
5
The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate.
Biology (Basel). 2023 Sep 29;12(10):1297. doi: 10.3390/biology12101297.
6
A Five-Year Retrospective Audit on Bone Protection Prescribing in Patients With Fragility Fractures in Primary Care.
Cureus. 2023 Sep 19;15(9):e45532. doi: 10.7759/cureus.45532. eCollection 2023 Sep.
7
Beneficial Effects of Zoledronic Acid on Tendons of the Osteogenesis Imperfecta Mouse (Oim).
Pharmaceuticals (Basel). 2023 Jun 2;16(6):832. doi: 10.3390/ph16060832.
8
Zoledronic Acid Implant Coating Results in Local Medullary Bone Growth.
Mol Pharm. 2022 Dec 5;19(12):4654-4664. doi: 10.1021/acs.molpharmaceut.2c00644. Epub 2022 Nov 15.
9
Phosphorylated and Phosphonated Low-Complexity Protein Segments for Biomimetic Mineralization and Repair of Tooth Enamel.
Adv Sci (Weinh). 2022 Feb;9(6):e2103829. doi: 10.1002/advs.202103829. Epub 2022 Jan 2.
10
Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw.
Clin Pharmacol Ther. 2021 Dec;110(6):1558-1569. doi: 10.1002/cpt.2397. Epub 2021 Aug 31.
本文引用的文献
1
Pharmacogenetics of osteoporosis: future perspectives.
Calcif Tissue Int. 2009 May;84(5):337-47. doi: 10.1007/s00223-009-9226-x. Epub 2009 Mar 7.
2
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Am J Med. 2009 Feb;122(2 Suppl):S14-21. doi: 10.1016/j.amjmed.2008.12.003.
3
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Calcif Tissue Int. 2009 Mar;84(3):171-9. doi: 10.1007/s00223-008-9207-5. Epub 2009 Jan 16.
4
Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone.
Calcif Tissue Int. 2008 Dec;83(6):414-24. doi: 10.1007/s00223-008-9193-7. Epub 2008 Nov 20.
5
Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy.
Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):481-8. doi: 10.1097/MED.0b013e32831a46be.
6
Bisphosphonate therapy for osteogenesis imperfecta.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD005088. doi: 10.1002/14651858.CD005088.pub2.
7
Bisphosphonates: mechanism of action and role in clinical practice.
Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
8
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis.
Curr Med Res Opin. 2008 Sep;24(9):2609-15. doi: 10.1185/03007990802352894. Epub 2008 Aug 6.
9
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
Blood. 2008 Oct 1;112(7):2709-12. doi: 10.1182/blood-2008-04-147884. Epub 2008 Jul 1.
10
Pharmacogenetics of bone treatments: the VDR and ERalpha gene story.
Pharmacogenomics. 2008 Jun;9(6):733-46. doi: 10.2217/14622416.9.6.733.
Zotero 插件